Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.6% – Here’s What Happened

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXPGet Free Report)’s share price traded down 3.6% during mid-day trading on Tuesday . The stock traded as low as $0.22 and last traded at $0.23. 15,196,699 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 60,758,266 shares. The stock had previously closed at $0.24.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Friday. They set a “hold” rating on the stock.

Get Our Latest Stock Analysis on Tonix Pharmaceuticals

Tonix Pharmaceuticals Stock Down 2.8 %

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock’s 50-day moving average price is $0.26 and its 200-day moving average price is $0.29. The stock has a market cap of $42.80 million, a price-to-earnings ratio of 0.00 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXPGet Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Further Reading

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.